Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

A Study of Erenumab Compared to Placebo for Children and Teenagers With Chronic Migraine to Test How Well It Works and How Safe It Is

Fast replyInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is studying chronic migraine in children aged 6 to less than 12 years and adolescents aged 12 to less than 18 years. Chronic migraine is a condition where a person experiences headaches on 15 or more days per month, with at least 8 of those days being migraine headaches. Migraines are severe headaches that can cause throbbing pain, often accompanied by sensitivity to light and sound, and sometimes nausea. The treatment being tested is erenumab, which is also known by its code name AMG 334. This medication is given as an injection under the skin. Some participants will receive erenumab while others will receive a placebo.

The purpose of the study is to evaluate how well erenumab works compared with placebo in reducing the number of monthly migraine days in children and adolescents with chronic migraine. The study will also look at the safety of erenumab in this age group. The main focus is to see if there is a change in the number of migraine days per month from the start of the study to weeks 9 through 12 of the treatment period.

The study involves a treatment period where participants will be randomly assigned to receive either erenumab or placebo. During this time, participants will need to keep a daily electronic diary to record their headaches and migraine symptoms. The study will measure various aspects including the change in monthly migraine days, the change in monthly headache days, and whether participants achieve at least a 50 percent reduction in their monthly migraine days. The study will also assess how migraines affect daily activities and school performance in these young participants.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline phase and electronic diary completion

    Before the treatment begins, you will enter a baseline phase that lasts at least 28 days.

    During this period, you will need to complete an electronic diary every day to record information about your headaches and migraines.

    You must complete the diary entries for at least 23 out of the last 28 days to continue in the trial. This means achieving at least 80% compliance with diary completion.

    The diary will help track how many days you experience headaches and how many of those are migraine days.

  2. Step 2

    Beginning of double-blind treatment phase

    After completing the baseline phase, you will begin the double-blind treatment phase. This means neither you nor your doctor will know whether you are receiving the actual medication or a placebo.

    You will be randomly assigned to receive either erenumab or a placebo.

    Erenumab is a solution for injection that will be administered under the skin (subcutaneous injection).

    The placebo looks identical to the actual medication but contains no active substance.

  3. Step 3

    Treatment administration during weeks 1 through 12

    You will receive injections of either erenumab or placebo during the treatment phase.

    The injections will be given under the skin at regular intervals as determined by the study protocol.

    You will continue to record your headaches and migraines in the electronic diary throughout this entire period.

  4. Step 4

    Primary evaluation period at weeks 9 through 12

    The main evaluation of how well the treatment works will focus on weeks 9 through 12, which corresponds to month 3 of the treatment phase.

    During this time, the number of days you experience migraines each month will be compared to the baseline period before treatment started.

    The goal is to see if there is a reduction in the number of monthly migraine days.

    You will continue completing the electronic diary daily to track your symptoms.

  5. Step 5

    Additional assessments during the treatment phase

    Throughout the first 12 weeks of treatment, additional measurements will be taken.

    These include tracking the number of headache days per month, not just migraine days.

    The severity of your migraine attacks will be recorded to see if they become less intense.

    You will complete a questionnaire called the modified PedMIDAS, which measures how much migraines affect your daily activities, school performance, and ability to participate in normal activities.

    The study will also assess whether you achieve at least a 50% reduction in monthly migraine days compared to the baseline period.

Who can join the trial?

7 criteria

  • The participant must be a child between 6 and 12 years old or a teenager between 12 and 18 years old at the time of signing the agreement to join the study.
  • The parent or legal representative, which means the adult who has the legal right to make decisions for the child, must provide written permission before any study activities begin.
  • The participant must have had a history of migraine, which is a type of severe headache that may come with or without aura (warning signs like seeing flashing lights or feeling tingling), for at least 12 months before joining the study. This must be confirmed by medical records or reports from the participant, parent, or legal representative.
  • The participant must have experienced at least 15 headache days per month, and at least 8 of those days must have been identified as migraine days, in each of the 3 months before screening for the study.
  • During the last 28 days of the initial observation period, the participant must have had at least 8 migraine days as recorded in the electronic diary, which is a digital tool used to track daily symptoms.
  • During the last 28 days of the initial observation period, the participant must have had at least 15 headache days as recorded in the electronic diary.
  • The participant must have completed the electronic diary entries on at least 80% of the days during the last 28 days of the initial observation period, which means filling out the diary on at least 23 out of 28 days.

Who cannot join the trial?

10 criteria

  • Pregnant women or women who are breastfeeding cannot take part in this study because the effects of the study medicine on unborn babies or nursing infants are not fully known.
  • You cannot participate if you have a history of cluster headaches, which are severe headaches that occur in groups or cycles, or hemiplegic migraine, a rare type of migraine that causes temporary weakness on one side of the body.
  • You are not eligible if you have experienced medication overuse headaches, which means using pain relief medicines too frequently, causing more headaches.
  • You cannot join if you have used onabotulinumtoxinA (also known as Botox, a medicine injected to prevent migraines) within 4 months before starting the study.
  • You are excluded if you have previously used medicines called CGRP inhibitors, which are drugs specifically designed to prevent migraines by blocking a protein in the body.
  • You cannot participate if you have used certain preventive migraine medications within specific time periods before the study begins, depending on the type of medicine.
  • You are not eligible if you have a serious medical condition affecting your heart, liver, kidneys, or other major organs that could make it unsafe for you to participate.
  • You cannot join if you have an active psychiatric disorder, which means a mental health condition that is not well controlled, or a history of drug or alcohol abuse within the past year.
  • You are excluded if you have any condition or illness that the study doctor believes would make it unsafe for you to participate or could affect the study results.
  • You cannot participate if you are allergic to the study medicine or any of its ingredients.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Erenumab

    is a medication used to prevent migraines. It works by blocking a protein in the body that is involved in causing migraine headaches. This medicine is given as an injection under the skin, usually once a month. In this study, erenumab is being tested to see if it can reduce the number of migraine days in children and teenagers who suffer from chronic migraines.

  • Placebo

    is an inactive substance that looks like the real medication but contains no active medicine. It is used in this study to compare against erenumab to help determine if erenumab is truly effective at reducing migraine days.

What is already known about the treatment

Erenumab – Erenumab is an injectable medication given under the skin that works by blocking a specific protein in the brain called CGRP, which is involved in causing migraine headaches. This medicine is approved for preventing chronic migraine, a condition where people experience headaches on 15 or more days per month, and it has been studied in both adults and children as young as 6 years old. By preventing CGRP from attaching to its receptors on nerve cells, erenumab helps reduce the frequency of migraine attacks. It belongs to a class of drugs called monoclonal antibodies, which are specially designed proteins that target specific molecules in the body.

Investigated diseases

Chronic Migraine – Chronic migraine is a neurological condition characterized by frequent headache episodes that occur on 15 or more days per month for at least three months. At least 8 of these monthly headache days must have features typical of migraine headaches. The headaches are often accompanied by symptoms such as nausea, sensitivity to light, and sensitivity to sound. This condition significantly impacts daily activities and quality of life due to the high frequency of attacks. Chronic migraine can develop from less frequent migraine patterns over time. The condition affects both adults and adolescents, causing recurring episodes of moderate to severe head pain.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2023-504928-26-00Protocol code20160354Estimated enrolment277 patientsSponsorAmgen Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).